Bioventures 2018 L.P. Mpm Sells 32,263 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) major shareholder Bioventures 2018 L.P. Mpm sold 32,263 shares of Entrada Therapeutics stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $7.17, for a total transaction of $231,325.71. Following the transaction, the insider directly owned 4,144,952 shares of the company’s stock, valued at approximately $29,719,305.84. This trade represents a 0.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Bioventures 2018 L.P. Mpm also recently made the following trade(s):

• On Wednesday, September 2nd, Bioventures 2018 L.P. Mpm sold 25,131 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.19, for a total transaction of $180,691.89.
• On Tuesday, September 1st, Bioventures 2018 L.P. Mpm sold 29,088 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.06, for a total transaction of $205,361.28.
• On Monday, August 31st, Bioventures 2018 L.P. Mpm sold 44,259 shares of Entrada Therapeutics stock. The stock was sold at an average price of $6.99, for a total transaction of $309,370.41.
• On Friday, August 28th, Bioventures 2018 L.P. Mpm sold 3,733 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.01, for a total transaction of $26,168.33.
• On Thursday, August 27th, Bioventures 2018 L.P. Mpm sold 38,922 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.20, for a total transaction of $280,238.40.

Entrada Therapeutics Stock Down 0.6%

Entrada Therapeutics stock opened at $7.13 on Friday. The company’s 50-day moving average price is $7.06 and its two-hundred day moving average price is $9.19. The stock has a market cap of $277.64 million, a P/E ratio of -1.80 and a beta of -0.25. Entrada Therapeutics, Inc. has a twelve month low of $5.02 and a twelve month high of $16.45.

Entrada Therapeutics (NASDAQ:TRDA) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). The firm had revenue of $0.90 million for the quarter, compared to the consensus estimate of $2.32 million. Entrada Therapeutics had a negative return on equity of 57.61% and a negative net margin of 3,537.73%. Equities analysts anticipate that Entrada Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. State of Wyoming bought a new stake in Entrada Therapeutics during the second quarter worth about $37,000. Russell Investments Group Ltd. increased its holdings in Entrada Therapeutics by 72.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company’s stock valued at $51,000 after buying an additional 3,707 shares during the period. Occudo Quantitative Strategies LP bought a new position in Entrada Therapeutics in the 2nd quarter valued at about $68,000. Jain Global LLC acquired a new position in shares of Entrada Therapeutics in the 3rd quarter valued at approximately $69,000. Finally, IHT Wealth Management LLC acquired a new position in shares of Entrada Therapeutics in the 2nd quarter valued at approximately $72,000. Institutional investors and hedge funds own 86.39% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on TRDA. Wall Street Zen raised shares of Entrada Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. HC Wainwright lowered shares of Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 8th. Roth Capital reiterated a “buy” rating and issued a $11.00 price objective on shares of Entrada Therapeutics in a research note on Wednesday, August 12th. Weiss Ratings upgraded shares of Entrada Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday. Finally, Guggenheim lowered their target price on shares of Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating on the stock in a report on Monday, June 8th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $17.75.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.